SCHEMBL6567085

SCHEMBL6567085

COCCNS(=O)(=O)c1ccccc1

nearest known ligand 0.81

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.81
ALDH1A1 P00352 13/20 0.74
LMNA P02545 4/20 0.74
HPGD P15428 2/20 0.74
KDM4E B2RXH2 2/20 0.74
SMN1; SMN2 Q16637 2/20 0.74
MAPT P10636 2/20 0.74
NPC1 O15118 1/20 0.74
RAB9A P51151 1/20 0.74
HTT P42858 3/20 0.66
ALOX15 P16050 1/20 0.66
PKM P14618 2/20 0.61
TSHR P16473 2/20 0.59
MEN1 O00255 2/20 0.59
KMT2A Q03164 2/20 0.59
POLB P06746 2/20 0.59
NPSR1 Q6W5P4 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6566896 0.90 ALDH1A1 (0.81) MAPK1ALDH1A1LMNAHPGDKDM4E
SCHEMBL15577722 0.90 ALDH1A1 (0.81) MAPK1ALDH1A1LMNAHPGDKDM4E
SCHEMBL7176062 0.89 MAPK1 (1.00) MAPK1ALDH1A1LMNAHPGDKDM4E
SCHEMBL6568078 0.88 MAPK1 (0.90) MAPK1ALDH1A1LMNAHPGDKDM4E
SCHEMBL4617091 0.86 MAPK1 (0.61) MAPK1ALDH1A1LMNAHPGDKDM4E
SCHEMBL12640166 0.85 ALDH1A1 (1.00) MAPK1ALDH1A1LMNAHPGDKDM4E
SCHEMBL12302132 0.84 ALDH1A1 (0.90) MAPK1ALDH1A1LMNAHPGDKDM4E
SCHEMBL12672469 0.83 ALDH1A1 (0.96) MAPK1ALDH1A1LMNAHPGDKDM4E
SCHEMBL24762147 0.82 ALDH1A1 (0.75) MAPK1ALDH1A1LMNAHPGDKDM4E
SCHEMBL7350215 0.82 MAPK1 (0.66) MAPK1ALDH1A1LMNAHPGDKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109415381-B Thiazolopyridine derivatives as GPR119 agonists 人类制药有限公司 2022-03-25 CN claimed
CN-111699189-B Modulators of beta-3 adrenergic receptors useful for treating or preventing heart failure and disorders associated therewith 艾尼纳制药公司 2025-02-18 CN disclosed
US-20230047816-A1 PFKFB3 INHIBITORS AND THEIR USES GERO PTE. LTD. (SG) 2023-02-16 US disclosed
WO-2022169755-A1 SULFONAMIDE SUBSTITUTED N-(1H-INDOL-7-YL) BENZENESULFONAMIDES AND USES THEREOF TRIANA BIOMEDICINES, INC. (US) 2022-08-11 WO disclosed
CN-109415381-B Thiazolopyridine derivatives as GPR119 agonists 人类制药有限公司 2022-03-25 CN disclosed
WO-2021143706-A1 SUBSTITUTED TRIAZINONES AS THYROID HORMONE RECEPTOR AGONISTS ECCOGENE (SHANGHAI) CO., LTD. (CN) 2021-07-22 WO disclosed
EP-2791120-A1 1,3,5 -TRIAZINE-2-AMINE DERIVATIVES, PREPARATION THEREOF AND DIAGNOSTIC AND THERAPEUTIC USE THEREOF SANOFI (FR) 2014-10-22 EP disclosed
WO-2013087643-A1 1,3,5 -TRIAZINE-2-AMINE DERIVATIVES, PREPARATION THEREOF AND DIAGNOSTIC AND THERAPEUTIC USE THEREOF SANOFI (FR) 2013-06-20 WO disclosed
WO-2010100144-A1 FUSED BICYCLIC COMPOUNDS AS INHIBITORS FOR PI3 KINASE MERCK SERONO S.A. (CH) 2010-09-10 WO disclosed
US-7781469-B2 Arylacetate derivatives having isoxazole skeleton SHIONOGI & CO., LTD. (JP) 2010-08-24 US disclosed
WO-2009133127-A1 FUSED BICYCLIC COMPOUNDS AND USE THEREOF AS PI3K INHIBITORS MERCK SERONO S.A. (CH) 2009-11-05 WO disclosed
US-20090062531-A1 Arylacetate Derivatives Having Isoxazole Skeleton SHIONOGI & CO., LTD. (JP) 2009-03-05 US disclosed
EP-1443041-A1 5-AMIDINO-2-HYDROXYBENZENESULFONAMIDE DERIVATIVES, MEDICINAL COMPOSITIONS CONTAINING THE SAME, MEDICINAL USE THEREOF AND INTERMEDIATES IN THE PRODUCTION THEREOF Kissei Pharmaceutical Co., Ltd. (JP) 2004-08-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230047816-A1 PFKFB3 INHIBITORS AND THEIR USES PFKFB3, PFKFB4, PFKFB1 MAPK1 1468/4885ALDH1A1 1943/4885LMNA 4383/4885
US-20090062531-A1 Arylacetate Derivatives Having Isoxazole Skeleton CYP2A7, CYP4X1, HAX1 MAPK1 2674/4885ALDH1A1 877/4885LMNA 2638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.